Theratechnologies pulls cross-border offering

Theratechnologies’ (TSX:TH) board of directors has decided to withdraw its public offering in Canada and the U.S. because of the expected offering price, which was not acceptable to the company. Shares of Theratechnologies have been on a downward spiral since the proposed offering was announced on Feb. 22, sliding from $5.01 to Tuesday’s close of [...]

Analysts hike price target on Theratechnologies

Versant Partners and Canaccord Genuity raised their price targets on Theratechnologies (TSX:TH) after the company signed a partnership with Sanofi-Aventis to distribute its Egrifta HIV treatment in Latin America, Africa and the Middle East, and confirmed that the U.S. selling price of the drug would be $23,900 (U.S.) a year, higher than previously assumed. Cannacord [...]

Theratechnologies picks Huss as president, CEO

Theratechnologies (TSX:TH) has named John-Michel Huss as president and CEO, succeeding Yves Rosconi, who previously informed the board of his decision to retire by the end of the year. Mr. Huss will assume the two posts in coming months. He was most recently chief of staff, office of the CEO, of Sanofi-Aventis in Paris and has [...]